Can we further optimize statin therapy to increase tolerability?

References

• Reiner Z. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol. 2013 Aug;10(8):453–464. PubMed PMID: 23736519.
   PubMed Web of Science ®Google Scholar
• Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the american heart association. Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38–e81. PubMed PMID: 30580575.
   PubMed Web of Science ®Google Scholar
• Lemstra M, Blackburn D, Crawley A, et al. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012 Sep-Oct;28(5):574–580. PubMed PMID: 22884278.
   PubMed Web of Science ®Google Scholar
• Spence JD, Dresser GK. Overcoming challenges with statin therapy. J Am Heart Assoc. 2016 Jan 27;5(1). PubMed PMID: 26819251; PubMed Central PMCID: PMCPMC4859367. DOI:10.1161/JAHA.115.002497.
   PubMed Web of Science ®Google Scholar
• Kotseva K, De Backer G, De Bacquer D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European society of cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019 Feb 10:2047487318825350. PubMed PMID: 30739508. DOI:10.1177/2047487318825350.
   Web of Science ®Google Scholar
• Simic I, Reiner Z. Adverse effects of statins - myths and reality. Curr Pharm Des. 2015;21(9):1220–1226. PubMed PMID: 25312733.
   PubMed Web of Science ®Google Scholar
• Ofori-Asenso R, Zoungas S, Liew D. Reinitiation of statin therapy after discontinuation: a meta-analysis. Mayo Clin Proc. 2018 May;93(5):666–668. PubMed PMID: 29728206.
   PubMed Web of Science ®Google Scholar
• Navar AM, Peterson ED, Li S, et al. Prevalence and Management of Symptoms associated with statin therapy in community practice: insights from the palm (patient and provider assessment of lipid management) registry. Circ Cardiovasc Qual Outcomes. 2018 Mar;11(3):e004249. PubMed PMID: 29545393; PubMed Central PMCID: PMCPMC5858190.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015 May 1;36(17):1012–1022. PubMed PMID: 25694464; PubMed Central PMCID: PMCPMC4416140.
   PubMed Web of Science ®Google Scholar
• Gupta A, Thompson D, Whitehouse A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian cardiac outcomes trial-lipid-lowering arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017 Jun 24;389(10088):2473–2481. PubMed PMID: 28476288.
   PubMed Web of Science ®Google Scholar
• Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013 Apr 2;158(7):526–534. PubMed PMID: 23546564; PubMed Central PMCID: PMCPMC3692286.
   PubMed Web of Science ®Google Scholar
• Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. Jama. 1988 Jul 8;260(2):239–241. PubMed PMID: 3290520.
   PubMed Web of Science ®Google Scholar
• Bitzur R, Cohen H, Kamari Y, et al. Intolerance to statins: mechanisms and management. Diabetes Care. 2013 Aug;36(Suppl 2):S325–30. PubMed PMID: 23882066; PubMed Central PMCID: PMCPMC3920796.
   PubMedGoogle Scholar
• Navar AM, Roe MT, White JA, et al. Medication Discontinuation in the IMPROVE-IT Trial. Circ Cardiovasc Qual Outcomes. 2019 Jan;12(1):e005041. PubMed PMID: 30630361.
   PubMed Web of Science ®Google Scholar
• Penson PE, Mancini GBJ, Toth PP, et al. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. J Cachexia Sarcopenia Muscle. 2018 Dec;9(6):1023–1033. PubMed PMID: 30311434; PubMed Central PMCID: PMCPMC6240752.
   PubMed Web of Science ®Google Scholar
• Vonbank A, Agewall S, Kjeldsen KP, et al. Comprehensive efforts to increase adherence to statin therapy. Eur Heart J. 2017 Aug 21;38(32):2473–2479. PubMed PMID: 28077470.
   PubMed Web of Science ®Google Scholar
• Marz W, Dippel FW, Theobald K, et al. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: real-world evidence from Germany. Atherosclerosis. 2018 Jan;268:99–107. PubMed PMID: 29197254.
   PubMed Web of Science ®Google Scholar
• Gitt AK, Lautsch D, Ferrieres J, et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the dyslipidemia international study II. Atherosclerosis. 2017 Nov;266:158–166. PubMed PMID: 29028484.
   PubMed Web of Science ®Google Scholar
• Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014 Oct;24(10):1057–1066. PubMed PMID: 24996502.
   PubMed Web of Science ®Google Scholar
• Reiner Z, Sonicki Z, Tedeschi-Reiner E. Physicians’ perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis. 2010 Dec;213(2):598–603. PubMed PMID: 20947087.
   PubMed Web of Science ®Google Scholar
• Rodriguez F, Maron DJ, Knowles JW, et al. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2019 Feb 13. PubMed PMID: 30758506. DOI:10.1001/jamacardio.2018.4936.
   Google Scholar
• Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018 Mar 26;20(4):21. PubMed PMID: 29582188; PubMed Central PMCID: PMCPMC6019613.
   PubMed Web of Science ®Google Scholar
• Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018 Sep;17(9):816–828. PubMed PMID: 30129477.
   PubMed Web of Science ®Google Scholar
• Kassardjian CD, Lennon VA, Alfugham NB, et al. Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol. 2015 Sep;72(9):996–1003. PubMed PMID: 26192196.
   PubMed Web of Science ®Google Scholar
• Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016 Feb 18;374(7):664–669. PubMed PMID: 26886523.
   PubMed Web of Science ®Google Scholar
• Essers D, Schaublin M, Kullak-Ublick GA, et al. Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase. Eur J Clin Pharmacol. 2019 Mar;75(3):409–416. PubMed PMID: 30430215.
   PubMed Web of Science ®Google Scholar
• Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002 Oct 1;137(7):581–585. PubMed PMID: 12353945.
   PubMed Web of Science ®Google Scholar
• Draeger A, Monastyrskaya K, Mohaupt M, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006 Sep;210(1):94–102. PubMed PMID: 16799920.
   PubMed Web of Science ®Google Scholar
• Mohaupt MG, Karas RH, Babiychuk EB, et al. Association between statin-associated myopathy and skeletal muscle damage. Cmaj. 2009 Jul 7;181(1–2):E11–8. PubMed PMID: 19581603; PubMed Central PMCID: PMCPMC2704421.
   PubMed Web of Science ®Google Scholar
• Pierno S, Didonna MP, Cippone V, et al. Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. Br J Pharmacol. 2006 Dec;149(7):909–919. PubMed PMID: 17031388; PubMed Central PMCID: PMCPMC2014683.
   PubMed Web of Science ®Google Scholar
• Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006 Aug;34(2):153–162. PubMed PMID: 16671104.
   PubMed Web of Science ®Google Scholar
• Mangravite LM, Engelhardt BE, Medina MW, et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature. 2013 Oct 17;502(7471):377–380. PubMed PMID: 23995691; PubMed Central PMCID: PMCPMC3933266.
   PubMed Web of Science ®Google Scholar
• Fieni F, Johnson DE, Hudmon A, et al. Mitochondrial Ca2+ uniporter and CaMKII in heart. Nature. 2014 Sep 25;513(7519):E1–2. PubMed PMID: 25254480; PubMed Central PMCID: PMCPMC4476531.
   PubMed Web of Science ®Google Scholar
• Ballard KD, Thompson PD. Does reduced creatine synthesis protect against statin myopathy? Cell Metab. 2013 Dec 3;18(6):773–774. PubMed PMID: 24315367; PubMed Central PMCID: PMCPMC3899594.
   PubMed Web of Science ®Google Scholar
• Taylor BA, Panza G, Ballard KD, et al. Creatine supplementation does not alter the creatine kinase response to eccentric exercise in healthy adults on atorvastatin. J Clin Lipidol. 2018 Sep - Oct;12(5):1305–1312. PubMed PMID: 29945780.
   PubMed Web of Science ®Google Scholar
• K Siddiqui M, Maroteau C, Veluchamy A, et al. A common missense variant of LILRB5 is associated with statin intolerance and myalgia. Eur Heart J. 2017 Dec 21;38(48):3569–3575. PubMed PMID: 29020356; PubMed Central PMCID: PMCPMC5837247.
   PubMed Web of Science ®Google Scholar
• Hanai J, Cao P, Tanksale P, et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest. 2007 Dec;117(12):3940–3951. PubMed PMID: 17992259; PubMed Central PMCID: PMCPMC2066198.
   PubMed Web of Science ®Google Scholar
• Suwa M, Egashira T, Nakano H, et al. Metformin increases the PGC-1alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. J Appl Physiol (1985). 2006 Dec;101(6):1685–1692. PubMed PMID: 16902066.
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. Jama. 2011 Jun 22;305(24):2556–2564. PubMed PMID: 21693744.
   PubMed Web of Science ®Google Scholar
• Elsaid O, Taylor B, Zaleski A, et al. Rationale for investigating metformin as a protectant against statin-associated muscle symptoms. J Clin Lipidol. 2017 Sep - Oct;11(5):1145–1151. PubMed PMID: 28764958.
   PubMed Web of Science ®Google Scholar
• Chung HR, Vakil M, Munroe M, et al. The impact of exercise on statin-associated skeletal muscle myopathy. PLoS One. 2016;11(12):e0168065. PubMed PMID: 27936249; PubMed Central PMCID: PMCPMC5148116.
   PubMed Web of Science ®Google Scholar
• Sinzinger H, O’Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol. 2004 Apr;57(4):525–528. PubMed PMID: 15025753; PubMed Central PMCID: PMCPMC1884475.
   PubMed Web of Science ®Google Scholar
• Elam MB, Majumdar G, Mozhui K, et al. Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge. PLoS One. 2017;12(8):e0181308. PubMed PMID: 28771594; PubMed Central PMCID: PMCPMC5542661.
   PubMed Web of Science ®Google Scholar
• Group SC, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789–799. PubMed PMID: 18650507.
   PubMed Web of Science ®Google Scholar
• Peyser B, Perry EP, Singh K, et al. Effects of delivering SLCO1B1 pharmacogenetic information in randomized trial and observational settings. Circ Genom Precis Med. 2018 Sep;11(9):e002228. PubMed PMID: 30354330.
   PubMed Web of Science ®Google Scholar
• Marz W, Laufs U. Leucocyte immunoglobulin-like receptor subfamily-B5 (LILRB5) genetic variation and statin-associated muscle symptoms: another piece in a puzzling puzzle. Eur Heart J. 2017 Dec 21;38(48):3576–3578. PubMed PMID: 29059353.
   PubMed Web of Science ®Google Scholar
• Awad K, Mikhailidis DP, Toth PP, et al. Efficacy and safety of alternate-day versus daily dosing of statins: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2017 Aug;31(4):419–431. PubMed PMID: 28741244.
   PubMed Web of Science ®Google Scholar
• Ruisinger JF, Backes JM, Gibson CA, et al. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol. 2009 Feb 1;103(3):393–394. PubMed PMID: 19166695.
   PubMed Web of Science ®Google Scholar
• Macchi C, Banach M, Corsini A, et al. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents. Eur J Prev Cardiol. 2019 Feb 18:2047487319831500. PubMed PMID: 30776916. DOI:10.1177/2047487319831500.
   Web of Science ®Google Scholar
• Stoekenbroek RM, Hartgers ML, Rutte R, et al. PCSK9 inhibitors in clinical practice: delivering on the promise? Atherosclerosis. 2018 Mar;270:205–210. PubMed PMID: 29254691.
   PubMed Web of Science ®Google Scholar
• Gurgoze MT, Muller-Hansma AHG, Schreuder MM, et al. Adverse events associated with PCSK9 inhibitors: a real-world experience. Clin Pharmacol Ther. 2019 Feb;105(2):496–504. PubMed PMID: 30053327.
   PubMed Web of Science ®Google Scholar
• Nishikido T, Ray KK. Inclisiran for the treatment of dyslipidemia. Expert Opin Investig Drugs. 2018 Mar;27(3):287–294. PubMed PMID: 29451410.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Banach M, Sahebkar A, et al. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Expert Opin Pharmacother. 2019 Feb 27:1–13. PubMed PMID: 30810432. DOI:10.1080/14656566.2019.1583209.
   Web of Science ®Google Scholar
• Ruscica M, Macchi C, Pavanello C, et al. Appropriateness of statin prescription in the elderly. Eur J Intern Med. 2018 Apr;50:33–40. PubMed PMID: 29310996.
   PubMed Web of Science ®Google Scholar